Bristol Myers Squibb
Opdivo
Hodgkin Lymphoma
Resolved
109days ago
Approval decision · Mar 20, 2026
What's at stake
A final FDA approval decision on Opdivo for Hodgkin Lymphoma is expected Mar 20, 2026.
Primary source
· SEC 8-K
verified 14h ago
“In addition, the European Commission approved Opdivo in combination with brentuximab vedotin for the treatment of children 5 years of age and older, adolescents, and adults up to 30 years of age with relapsed or refractory cHL after one pri”